TD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
at www.tipranks.com (Mon, 27-Apr 10:36 AM)
Jazz Pharmaceuticals Projects Continued Revenue Growth into 2026, Driven by Neuroscience and Oncology Expansion
Market Chameleon (Wed, 25-Feb 11:18 AM)
